Acadia Pharmaceuticals Inc. (ACAD) Financials
Key financial figures for Acadia Pharmaceuticals Inc. (Q3 2026).
Acadia reported Q3 2026 GAAP total revenues of $342 million, up 23% from $279 million a year earlier, and raised its 2026 DAYBUE net sales guidance to $505 to $520 million. Total revenues were $342.3 million versus $278.6 million in Q3 2025 (+23% GAAP; +22% against non-GAAP adjusted $281 million for Q3 2025). DAYBUE net sales were $140 million, up 39% from $101 million, which the company attributes to strong uptake of DAYBUE STIX. NUPLAZID GAAP net sales were $202 million, up 14% GAAP (up 12% against non-GAAP adjusted $180 million). On the outlook: 2026 GAAP guidance: total revenues $1.265 to $1.295 billion (previous $1.24 to $1.30 billion); NUPLAZID net product sales $760 to $775 million (previous $760 to $790 million); DAYBUE global net product sales $505 to $520 million (previous $480 to $510 million); R&D expense $325 to $340 million (previous $355 to $380 million); SG&A expense $665 to $685 million (previous $660 to $700 million). Figures are for Q3 2026, as Acadia Pharmaceuticals Inc. reported them.
- Revenue
- $342M
- Net Income
- $54M
- EPS
- $0.31
- Total Assets
- $1.8B
- Operating Cash Flow
- $12M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $342M | $54M | $0.31 | 20.95% | $10M |
| Q2 FY2026 | $308M | $32M | $0.18 | 12.29% | $124M |
| Q1 FY2026 | $268M | $4M | $0.02 | -1.72% | $29M |
| Q4 FY2025 | $284M | $274M | $1.60 | 6.12% | -$53M |
| Q3 FY2025 | $279M | $72M | $0.42 | 12.83% | $74M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $1.1B | $391M | $2.30 | 9.78% | $105M |
| FY2024 | $958M | $226M | $1.36 | 24.1% | $157M |
| FY2023 | $726M | -$61M | -$0.37 | -10.1% | -$23M |
Frequently asked questions
What was Acadia Pharmaceuticals Inc.'s revenue last quarter?
Acadia Pharmaceuticals Inc. reported revenue of $342.3 million for Q3 FY2026, up 22.8% from the same period a year earlier.
Is Acadia Pharmaceuticals Inc. profitable?
Yes. Acadia Pharmaceuticals Inc. reported net income of $53.5 million for Q3 FY2026, a net margin of 15.64% on revenue.
How has Acadia Pharmaceuticals Inc.'s margin trended?
Operating margin was 20.95% in Q3 FY2026, compared with 12.83% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Acadia Pharmaceuticals Inc. generate?
Acadia Pharmaceuticals Inc. generated free cash flow of $10.3 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Acadia Pharmaceuticals Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.